OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison
Carel W. le Roux, Emily R. Hankosky, Duzhe Wang, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 9, pp. 2626-2633
Open Access | Times Cited: 17
Carel W. le Roux, Emily R. Hankosky, Duzhe Wang, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 9, pp. 2626-2633
Open Access | Times Cited: 17
Showing 17 citing articles:
Effectiveness and safety of drugs for obesity
Kristina H. Lewis, Caroline E Sloan, Daniel H. Bessesen, et al.
BMJ (2024), pp. e072686-e072686
Open Access | Times Cited: 22
Kristina H. Lewis, Caroline E Sloan, Daniel H. Bessesen, et al.
BMJ (2024), pp. e072686-e072686
Open Access | Times Cited: 22
Efficacy and safety of tirzepatide, GLP ‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
Xin‐Hui Pan, B.C. Tan, Yip Han Chin, et al.
Obesity (2024) Vol. 32, Iss. 5, pp. 840-856
Closed Access | Times Cited: 18
Xin‐Hui Pan, B.C. Tan, Yip Han Chin, et al.
Obesity (2024) Vol. 32, Iss. 5, pp. 840-856
Closed Access | Times Cited: 18
Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study
Mohammad H. Jamal, Mohsen Alhashemi, Carol Dsouza, et al.
Obesity Surgery (2024) Vol. 34, Iss. 4, pp. 1324-1332
Closed Access | Times Cited: 12
Mohammad H. Jamal, Mohsen Alhashemi, Carol Dsouza, et al.
Obesity Surgery (2024) Vol. 34, Iss. 4, pp. 1324-1332
Closed Access | Times Cited: 12
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 11
Anna Giannakogeorgou, Michael Roden
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 11
Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition
Fabian Stoll, Tobias Kantowski, Jonas Laaser, et al.
Obesity Research & Clinical Practice (2025) Vol. 19, Iss. 1, pp. 63-69
Open Access | Times Cited: 1
Fabian Stoll, Tobias Kantowski, Jonas Laaser, et al.
Obesity Research & Clinical Practice (2025) Vol. 19, Iss. 1, pp. 63-69
Open Access | Times Cited: 1
Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study
Matthew Anson, Alex E. Henney, Nicholas Broadwell, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102777-102777
Open Access | Times Cited: 6
Matthew Anson, Alex E. Henney, Nicholas Broadwell, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102777-102777
Open Access | Times Cited: 6
Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis
Deep Dutta, A B Kamrul-Hasan, Lakshmi Nagendra, et al.
touchREVIEWS in Endocrinology (2024) Vol. 20, Iss. 2
Open Access | Times Cited: 6
Deep Dutta, A B Kamrul-Hasan, Lakshmi Nagendra, et al.
touchREVIEWS in Endocrinology (2024) Vol. 20, Iss. 2
Open Access | Times Cited: 6
Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity with or without type 2 diabetes: A Systematic Review of Phase 3 Clinical Trials
Akriti Singh, Awadhesh Kumar Singh, Ritu Singh, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2025) Vol. 19, Iss. 3, pp. 103212-103212
Closed Access
Akriti Singh, Awadhesh Kumar Singh, Ritu Singh, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2025) Vol. 19, Iss. 3, pp. 103212-103212
Closed Access
Patients With Severe Obesity Are Made Eligible for Complex Abdominal Wall Repair After Preoptimization With GLP‐1 Agonists: Results of a Bicentric Pilot Study
B. Romain, Vincent Pfirsch, Simone Manfredelli, et al.
World Journal of Surgery (2025)
Open Access
B. Romain, Vincent Pfirsch, Simone Manfredelli, et al.
World Journal of Surgery (2025)
Open Access
EFICÁCIA COMPARADA ENTRE SEMAGLUTIDA E TIRZEPATIDA PARA TRATAMENTO DE OBESIDADE: UMA REVISÃO DE LITERATURA
Júlia Moreno Turchetto, Gabriela Faria, Emilene Dias Fiuza Ferreira
Revista Foco (2025) Vol. 18, Iss. 3, pp. e8015-e8015
Open Access
Júlia Moreno Turchetto, Gabriela Faria, Emilene Dias Fiuza Ferreira
Revista Foco (2025) Vol. 18, Iss. 3, pp. e8015-e8015
Open Access
Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3–36 in the suppression of food, drug-seeking, and anxiogenesis
Yasmina Dumiaty, Brett M. Underwood, Jenny Phy-Lim, et al.
Neuropeptides (2024) Vol. 105, pp. 102427-102427
Open Access | Times Cited: 4
Yasmina Dumiaty, Brett M. Underwood, Jenny Phy-Lim, et al.
Neuropeptides (2024) Vol. 105, pp. 102427-102427
Open Access | Times Cited: 4
Retatrutide showing promise in obesity (and type 2 diabetes)
Sheila A Doggrell
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 11, pp. 997-1001
Closed Access | Times Cited: 8
Sheila A Doggrell
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 11, pp. 997-1001
Closed Access | Times Cited: 8
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
Ronald Goldenberg, Hwee Teoh, Subodh Verma
Current Opinion in Cardiology (2023) Vol. 38, Iss. 6, pp. 539-545
Closed Access | Times Cited: 5
Ronald Goldenberg, Hwee Teoh, Subodh Verma
Current Opinion in Cardiology (2023) Vol. 38, Iss. 6, pp. 539-545
Closed Access | Times Cited: 5
Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)
Mark A. Moyad
Current Urology Reports (2023) Vol. 24, Iss. 11, pp. 515-525
Closed Access | Times Cited: 4
Mark A. Moyad
Current Urology Reports (2023) Vol. 24, Iss. 11, pp. 515-525
Closed Access | Times Cited: 4
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Ibrahim S. Alhomoud, Azita H. Talasaz, Preethi Chandrasekaran, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2024) Vol. 44, Iss. 9, pp. 738-752
Closed Access | Times Cited: 1
Ibrahim S. Alhomoud, Azita H. Talasaz, Preethi Chandrasekaran, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2024) Vol. 44, Iss. 9, pp. 738-752
Closed Access | Times Cited: 1
Tirzepatide - A Revolution in Obesity Treatment?
Aleksandra Jaroń, Katarzyna Jastrzębska, Klara Wojciechowska, et al.
Quality in Sport (2024) Vol. 17, pp. 53102-53102
Open Access
Aleksandra Jaroń, Katarzyna Jastrzębska, Klara Wojciechowska, et al.
Quality in Sport (2024) Vol. 17, pp. 53102-53102
Open Access
Tirzepatide for overweight and obesity management
Malak Hamza, Dimitris Papamargaritis, Melanie J. Davies
Expert Opinion on Pharmacotherapy (2024), pp. 1-19
Open Access
Malak Hamza, Dimitris Papamargaritis, Melanie J. Davies
Expert Opinion on Pharmacotherapy (2024), pp. 1-19
Open Access
